Unlocking the potential of the 3-hydroxykynurenine/kynurenic acid ratio: a promising biomarker in adolescent major depressive disorder
European Archives of Psychiatry and Clinical Neuroscience · 2025
DOI: 10.1007/s00406-024-01815-x ↗Kurz gefasst
Fachartikel in der Zeitschrift European Archives of Psychiatry and Clinical Neuroscience, 2025. Verfasst von Zhihan Ye und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Shanghai East Hospital, Tongji University School of Medicine, 150 Ji Mo Road, Shanghai, 200120, China. Hauptthemen laut MEDLINE: Kynurenine, Major Depressive Disorder, Kynurenic Acid. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: Shanghai Municipal Health Commission, National Natural Science Foundation of China.
Abstract (Originalsprache)
Metabolites disruptions in tryptophan (TRP) and kynurenine pathway (KP) are believed to disturb neurotransmitter homeostasis and contribute to depressive symptoms. This study aims to investigate serum levels of KP metabolites in adolescent major depressive disorder (AMDD), and examine their relationship with depression severities. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used to analyze serum levels of TRP, kynurenic acid (KYNA), kynurenine (KYN), and 3-hydroxy-kynurenine (3-HK) in 143 AMDD participants and 98 healthy controls (HC). Clinical data, including Children's Depression Inventory (CDI) scores, were collected and analyzed using statistical methods, such as ANOVA, logistic regression, Receiver operating characteristic curve analysis and a significance level of p < 0.05 was used for all analyses. AMDD showed significantly decreased serum levels of KYNA (-25.5%), KYN (-14.2%), TRP (-11.0%) and the KYNA/KYN ratio (-11.9%) compared to HC (p < 0.01). Conversely, significant increases were observed in 3-HK levels (+50.4%), the 3-HK/KYNA ratio (+104.3%) and the 3-HK/KYN ratio (+93.0%) (p < 0.01). Logistic regression analysis identified increased level of 3-HK as a contributing factor to AMDD, while increased level of KYNA acted as a protective factor against AMDD. The 3-HK/KYNA ratio demonstrated an area under the curve (AUC) of 0.952. This study didn't explore AMDD's inflammatory status and its metabolites relationship explicitly. These findings indicate that metabolites of TRP and KP may play a crucial role in the pathogenesis of AMDD, emphasizing the potential of the 3-HK/KYNA ratio as a laboratory biomarker for early detection and diagnosis of AMDD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory, Shanghai East Hospital, Tongji University School of Medicine, 150 Ji Mo Road, Shanghai, 200120, China.
- Department of Psychosomatic Medicine, Shanghai East Hospital, Tongji University School of Medicine, 150 Ji Mo Road, Shanghai, 200120, China.
- Department of Psychosomatic Medicine, Shanghai East Hospital, Tongji University School of Medicine, 150 Ji Mo Road, Shanghai, 200120, China. kangchuanyuan@tongji.edu.cn.
Förderung
- Shanghai Municipal Health Commission
- National Natural Science Foundation of China
Zitieren
APA
Ye, Z., Yang, S., Lu, L., Zong, M., Fan, L., & Kang, C. (2025). Unlocking the potential of the 3-hydroxykynurenine/kynurenic acid ratio: a promising biomarker in adolescent major depressive disorder. European Archives of Psychiatry and Clinical Neuroscience. https://doi.org/10.1007/s00406-024-01815-x
Vancouver
Ye Z, Yang S, Lu L, Zong M, Fan L, Kang C. Unlocking the potential of the 3-hydroxykynurenine/kynurenic acid ratio: a promising biomarker in adolescent major depressive disorder. European Archives of Psychiatry and Clinical Neuroscience. 2025. doi:10.1007/s00406-024-01815-x
BibTeX
@article{Ye2025,
author = {Ye, Zhihan and Yang, Shuran and Lu, Liu and Zong, Ming and Fan, Lieying and Kang, Chuanyuan},
title = {Unlocking the potential of the 3-hydroxykynurenine/kynurenic acid ratio: a promising biomarker in adolescent major depressive disorder},
journal = {European Archives of Psychiatry and Clinical Neuroscience},
year = {2025},
doi = {10.1007/s00406-024-01815-x}
}
EUVIMED